Flagstaff, AZ and London (April 16, 2012)—W. L. Gore & Associates (Gore) joined with leaders across the vascular and endovascular community in honoring four European physicians as Pioneers in Performance. The biennial award acknowledges exceptional work in the field of vascular and endovascular therapy, including aortic and lower-limb bypass and dialysis access surgery.
2012 winners were selected by past award recipients in four categories that correspond with different aspects of clinical collaboration. Through popular vote on pioneersinperformance.com, the broader medical community chose to award the following winners at a special celebration during the 34th Charing Cross International Symposium held in London, UK, April 14-17, 2012.
Professor Roger Greenhalgh, MD, a past recipient of the award, commented, "Pioneers in Performance recognises the extraordinary achievements made by proven leaders in our field to advance open and endovascular surgery and improve patient outcomes. This year's honorees exemplify world class excellence through innovation, critical thinking, education, research, and collaboration." Professor Greenhalgh is Emeritus Professor of Surgery and Head of Imperial College London Vascular Research Group and Chairman of the Charing Cross Symposium.
"We congratulate these European physicians who have demonstrated unrelenting dedication to the vascular community," said Ryan Takeuchi, Gore Aortic Business Leader. "In the continued pursuit of new, innovative treatments that improve the lives of patients, the contributions by these physicians are invaluable to advancing vascular and endovascular therapy."
The collaboration between Gore and physician pioneers has resulted in the development of minimally invasive treatment options for safely and effectively managing patients with aneurysms including the Conformable GORE® TAG® Thoracic Endoprosthesis and the GORE® EXCLUDER® AAA Endoprosthesis. These important partnerships have also yielded first-in-class products such as the GORE® VIABAHN® Endoprosthesis with CARMEDA® Bioactive Surface, which is used to treat patients with peripheral vascular disease (PVD), and the GORE® PROPATEN® Vascular Graft for peripheral use, including lower-limb bypass and dialysis access surgery.
The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 30 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac and general surgery. Gore was recently named one of the best companies to work for by Fortune magazine for the 15th consecutive year. For more information, visit www.goremedical.com.
In its 34th year, the Charing Cross International Symposium, held in London, is an educational forum, which takes place over four days. The plenary sessions run in a logical sequence starting with carotids and the lower limb on Saturday, the abdominal aorta on Sunday, the thoracic aorta and more carotids on Monday, renals and venous on Tuesday. Once again, a world class faculty discusses controversial topics, challenges the evidence, and takes part in a series of head-to-head debates to reach a consensus after discussion. www.cxsymposium.com.
Products listed may not be available in all markets. GORE®, EXCLUDER®, PIONEERS IN PERFORMANCE, PROPATEN®, TAG®, VIABAHN®, and designs are trademarks of W. L. Gore & Associates.
Kena Hudson or Tony Stephenson
Chempetitive Group for W. L. Gore & Associates
(510) 908-0966 or +44-(0)20-3159-4145
[email protected]